NCT04053764 - Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 10, 2019

Primary Completion Date

March 20, 2023

Study Completion Date

March 20, 2023

Conditions

Sickle Cell Disease (SCD)

Interventions

DRUG

Crizanlizuamb

Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab

DRUG

Standard of Care

HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)

Trial Locations (24)

1434

Novartis Investigative Site, Tripoli

27858

East Carolina University BrodySchool of Med 3, Greenville

31100

Novartis Investigative Site, Antakya / Hatay

35233

University of Alabama Birmingham, Birmingham

38163

Univ of Tenn Health Sciences Ctr, Memphis

41221

Novartis Investigative Site, Larissa

60612

University of Illinois Hospital and Health Sciences System ., Chicago

70809

Our Lady of the Lake Regional Medic ., Baton Rouge

75015

Novartis Investigative Site, Paris

77030

University of Texas Health Science Center at Houston, Houston

94010

Novartis Investigative Site, Créteil

20.211-030

Novartis Investigative Site, Rio de Janeiro

01232-010

Novartis Investigative Site, São Paulo

90035-003

Novartis Investigative Site, Porto Alegre

115 27

Novartis Investigative Site, Athens

DO8

Novartis Investigative Site, Dublin

1105 AZ

Novartis Investigative Site, Amsterdam

0801

Novartis Investigative Site, Panama City

08035

Novartis Investigative Site, Barcelona

01250

Novartis Investigative Site, Adana

01330

Novartis Investigative Site, Adana

SE1 9RT

Novartis Investigative Site, London

SE5 9RS

Novartis Investigative Site, London

W12 0HS

Novartis Investigative Site, London